Last reviewed · How we verify

NCT06982833

Trunk Restraint in Multiple Sclerosis

Completed NA Last updated 21 May 2025
What this trial tests

NA trial testing Trunk restraint in Multiple Sclerosis in 96 participants. Completed in 15 April 2025.

Timeline
10 March 2025
Primary endpoint
10 April 2025
15 April 2025

Quick facts

Lead sponsorZonguldak Bulent Ecevit University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment96
Start date10 March 2025
Primary completion10 April 2025
Estimated completion15 April 2025
Sites2 locations across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Zonguldak Bulent Ecevit University

Who can join

Adults 18 to 75, any sex, with Multiple Sclerosis or Healthy Control. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study examined the effect of trunk restraint on upper extremity functionality in patients with Multiple Sclerosis (MS).The study included 66 MS patients over the age of 18 and 30 healthy individuals. Participants' upper extremity functions were assessed. Their trunks were then restrained and their upper extremity functions were assessed again. The patients' level of disability (EDSS), trunk control (Trunk Impairment Scale - TIS), upper extremity functionality (Nine Hole Peg Test- 9HPT), were evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Zonguldak Bulent Ecevit University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06982833.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing